Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | XBP1 | P17861 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044817 | 0.81 | PTGS2 (0.59) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL31626700 | 0.81 | PTGS2 (0.59) | PTGS2MAPTRAB9ANPC1XBP1 | |
| Pseudoguaianolide SCHEMBL31387995 | 0.80 | PTGS2 (0.55) | PTGS2MAPTRAB9ANPC1XBP1 | |
| Burrodin SCHEMBL30072218 | 0.79 | PTGS2 (1.00) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL26240701 | 0.79 | PTGS2 (0.49) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL6424628 | 0.75 | PTGS2 (0.53) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL30047291 | 0.69 | PTGS2 (0.47) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL16641594 | 0.69 | NPC1 (0.60) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL23106991 | 0.68 | MAPT (0.49) | PTGS2MAPTRAB9ANPC1XBP1 | |
| SCHEMBL31237447 | 0.68 | PTGS2 (0.57) | PTGS2MAPTRAB9ANPC1XBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243476-A1 | PLANT LECTINS AS CARRIERS OF ASSOCIATED DRUG SUBSTANCES INTO ANIMAL AND HUMAN CELLS | Biostrategies LC | 2025-07-31 | — | — | US | claimed |
| US-20250002565-A1 | HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF | COTROPIA JOSEPH (US) | 2025-01-02 | — | — | US | claimed |
| WO-2024178091-A1 | MATERIALS AND METHODS FOR THERAPY OF THE MUSCULOSKELETAL SYSTEM AND OTHER TISSUES | Biostrategies LC (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240277802-A1 | Materials and Methods for Therapy of the Musculoskeletal System and Other Tissues | Biostrategies LC | 2024-08-22 | — | — | US | claimed |
| EP-4402167-A1 | HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF | Cotropia, Joseph (US) | 2024-07-24 | — | — | EP | claimed |
| US-20230140157-A1 | PLANT LECTINS AS CARRIERS OF ASSOCIATED DRUG SUBSTANCES INTO ANIMAL AND HUMAN CELLS | Biostrategies LC | 2023-05-04 | — | — | US | claimed |
| WO-2023043880-A1 | HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF | COTROPIA JOSEPH (US) | 2023-03-23 | — | — | WO | claimed |
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | disclosed |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-28 | — | — | US | disclosed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302983-A1 | Saponin Conjugates | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| US-20220218837-A1 | DRUG CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-07-14 | — | — | US | disclosed |
| US-11377649-B2 | Plant lectins as carriers of associated drug substances into animal and human cells | Biostrategies LC (US) | 2022-07-05 | — | — | US | disclosed |
| EP-4015003-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022103263-A1 | RODENTICIDE | METAMETA RESEARCH B.V. (NL) | 2022-05-19 | — | — | WO | disclosed |
| US-20220152213-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2022-05-19 | — | — | US | disclosed |
| US-11312751-B2 | MHC class I epitope delivering polypeptides | MOLECULAR TEMPLATES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302983-A1 | Saponin Conjugates | EPCAM, CD47, SHBG | PTGS2 1886/4885MAPT 4204/4885RAB9A 3979/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | PTGS2 3910/4885MAPT 3753/4885RAB9A 2151/4885 |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, EGFR | PTGS2 3604/4885MAPT 3868/4885RAB9A 3465/4885 |
| US-20220218837-A1 | DRUG CONJUGATE | OSTC, ADCY7, ADCY3 | PTGS2 2683/4885MAPT 4047/4885RAB9A 3950/4885 |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | CD40, FCGR1A, TNFSF10 | PTGS2 3395/4885MAPT 4452/4885RAB9A 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.